{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:59:57Z","timestamp":1785477597529,"version":"3.56.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,30]]},"DOI":"10.7759\/cureus.113696","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:26:44Z","timestamp":1785475604000},"source":"Crossref","is-referenced-by-count":0,"title":["Salvage Re-transurethral Resection of Prostate as a Diagnostic and Therapeutic Bridge in Treatment-Emergent Neuroendocrine Prostate Cancer: A Multimodal Management Paradigm"],"prefix":"10.7759","author":[{"given":"Lakshmi","family":"Kandhan L","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Ramana","family":"Korrapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Yedulla Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velmurugan","family":"Palaniyandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hariharasudhan","family":"Sekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram","family":"Krishnamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.926585","article-title":"The role of epigenetic change in therapy-induced neuroendocrine prostate cancer lineage plasticity","volume":"13","author":"Storck WK","year":"2022","unstructured":"Storck WK, May AM, Westbrook TC, Duan Z, Morrissey C, Yates JA, Alumkal JJ. The role of epigenetic change in therapy-induced neuroendocrine prostate cancer lineage plasticity. Front Endocrinol (Lausanne). 2022, 13:926585. 10.3389\/fendo.2022.926585","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and biological features of neuroendocrine prostate cancer","volume":"23","author":"Yamada Y","year":"2021","unstructured":"Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep. 2021, 23:15. 10.1007\/s11912-020-01003-9","journal-title":"Curr Oncol Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v12.i13.2143","article-title":"Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: identification, prognosis and survival, genetic and epigenetic factors","volume":"12","author":"Wishahi M","year":"2024","unstructured":"Wishahi M. Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: identification, prognosis and survival, genetic and epigenetic factors. World J Clin Cases. 2024, 12:2143-6. 10.12998\/wjcc.v12.i13.2143","journal-title":"World J Clin Cases"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.571308","article-title":"Treatment-emergent neuroendocrine prostate cancer: a clinicopathological and immunohistochemical analysis of 94 cases","volume":"10","author":"Zhang Q","year":"2020","unstructured":"Zhang Q, Han Y, Zhang Y, Liu D, Ming J, Huang B, Qiu X. Treatment-emergent neuroendocrine prostate cancer: a clinicopathological and immunohistochemical analysis of 94 cases. Front Oncol. 2020, 10:571308. 10.3389\/fonc.2020.571308","journal-title":"Front Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14970","article-title":"Management of hydronephrosis after radical cystectomy and urinary diversion for bladder cancer: a single tertiary center experience","volume":"29","author":"Tanaka T","year":"2022","unstructured":"Tanaka T, Shindo T, Hashimoto K, Kobayashi K, Masumori N. Management of hydronephrosis after radical cystectomy and urinary diversion for bladder cancer: a single tertiary center experience. Int J Urol. 2022, 29:1046-53. 10.1111\/iju.14970","journal-title":"Int J Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36253-1","article-title":"Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer","volume":"14","author":"Chakraborty G","year":"2023","unstructured":"Chakraborty G, Gupta K, Kyprianou N. Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer. Nat Commun. 2023, 14:567. 10.1038\/s41467-023-36253-1","journal-title":"Nat Commun"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/life15050797","article-title":"Local therapy can enhance the prognosis of certain patients with pathologically diagnosed neuroendocrine prostate carcinoma","volume":"15","author":"Kimura S","year":"2025","unstructured":"Kimura S, Terada N, Soumiya S, et al.. Local therapy can enhance the prognosis of certain patients with pathologically diagnosed neuroendocrine prostate carcinoma. Life (Basel). 2025, 15:797. 10.3390\/life15050797","journal-title":"Life (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00713-8","article-title":"Integrated multi-omics assessment of lineage plasticity in a prostate cancer patient with brain and dural metastases","volume":"8","author":"Ludwig ML","year":"2024","unstructured":"Ludwig ML, Moline D, Horrmann A, et al.. Integrated multi-omics assessment of lineage plasticity in a prostate cancer patient with brain and dural metastases. NPJ Precis Oncol. 2024, 8:215. 10.1038\/s41698-024-00713-8","journal-title":"NPJ Precis Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran H","year":"2019","unstructured":"Beltran H, Hruszkewycz A, Scher HI, et al.. The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res. 2019, 25:6916-24. 10.1158\/1078-0432.CCR-19-1423","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/bco2.212","article-title":"Genomic alterations in neuroendocrine prostate cancer: a systematic review and meta-analysis","volume":"4","author":"Chen J","year":"2023","unstructured":"Chen J, Shi M, Chuen Choi SY, Wang Y, Lin D, Zeng H, Wang Y. Genomic alterations in neuroendocrine prostate cancer: a systematic review and meta-analysis. BJUI Compass. 2023, 4:256-65. 10.1002\/bco2.212","journal-title":"BJUI Compass"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu P","year":"2017","unstructured":"Mu P, Zhang Z, Benelli M, et al.. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017, 355:84-8. 10.1126\/science.aah4307","journal-title":"Science"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02255-y","article-title":"Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation","volume":"41","author":"Merkens L","year":"2022","unstructured":"Merkens L, Sailer V, Lessel D, et al.. Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation. J Exp Clin Cancer Res. 2022, 41:46. 10.1186\/s13046-022-02255-y","journal-title":"J Exp Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca V","year":"2019","unstructured":"Conteduca V, Oromendia C, Eng KW, et al.. Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019, 121:7-18. 10.1016\/j.ejca.2019.08.011","journal-title":"Eur J Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.778758","article-title":"Neuroendocrine carcinoma as an independent prognostic factor for patients with prostate cancer: a population-based study","volume":"12","author":"Yao J","year":"2021","unstructured":"Yao J, Liu Y, Liang X, Shao J, Zhang Y, Yang J, Zheng M. Neuroendocrine carcinoma as an independent prognostic factor for patients with prostate cancer: a population-based study. Front Endocrinol (Lausanne). 2021, 12:778758. 10.3389\/fendo.2021.778758","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1912","article-title":"A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers","volume":"25","author":"Beltran H","year":"2019","unstructured":"Beltran H, Oromendia C, Danila DC, et al.. A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers. Clin Cancer Res. 2019, 25:43-51. 10.1158\/1078-0432.CCR-18-1912","journal-title":"Clin Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1211","article-title":"Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer: results from the phase 1b DeLLpro-300 study","volume":"31","author":"Aggarwal R","year":"2025","unstructured":"Aggarwal R, Rottey S, Bernard-Tessier A, et al.. Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer: results from the phase 1b DeLLpro-300 study. Clin Cancer Res. 2025, 31:3854-63. 10.1158\/1078-0432.CCR-25-1211","journal-title":"Clin Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/516794-salvage-re-transurethral-resection-of-prostate-as-a-diagnostic-and-therapeutic-bridge-in-treatment-emergent-neuroendocrine-prostate-cancer-a-multimodal-management-paradigm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:26:44Z","timestamp":1785475604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/516794-salvage-re-transurethral-resection-of-prostate-as-a-diagnostic-and-therapeutic-bridge-in-treatment-emergent-neuroendocrine-prostate-cancer-a-multimodal-management-paradigm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.113696","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}